Adjustments of warrants of series 2019/2020
Press release: Uppsala, July 8 2020. Dicot AB (publ) ("Dicot") will, in accordance with the terms for the warrants 2019/2020, carry out a recalculation in accordance with the warrant terms as a result of the latest completed rights issue of units published on April 23, 2020. There will be an adjustment of both subscription price and the number of shares that each warrant entitles to subscribe for. Information regarding the adjustments of option terms is shown below.
Warrants of series 2019/2020
Adjustment of the subscription price for subscription of shares through exercise of the warrants series 2019/2020 will take place after the ordinary measurement period September 14, 2020 to September 25, 2020.
Adjustment will take place in accordance with section 18.3 of previously published terms for warrants 2019/2020. The adjustment may result in a subscription price that is less than the floor of SEK 2.60 stated in item 16 of the terms for warrants 2019/2020.
Final adjustment will be published via press release after the end of the measurement period on September 25, 2020, but before the subscription period which runs from October 1, 2020 to October 15, 2020.
Full terms for the warrants 2019/2020 can be found on Dicot's website: https://www.dicot.se/media/203834/villkor-foer-teckningsoptioner-av-serie-to1-v2.pdf
About Dicot AB
Dicot is a pharmaceutical company focused on drug discovery and the development of novel lifestyle drugs to enrich patients' lives. The Company develops and manufactures medicines for the treatment of erectile dysfunction and premature ejaculation. The company's lead product, Libiguin®, for the treatment of sexual dysfunctions, is in a stage of pre-clinical development. Dicot is listed on the Spotlight Stock Market and has approximately 900 shareholders. For more information see www.dicot.se.
This press release is not an offer to subscribe for shares or units in Dicot and investors should not subscribe or acquire any securities. Invitation to concerned persons to subscribe for shares in Dicot will only be made through the EU growth prospectus. This press release shall not, directly or indirectly, be released, published or distributed in or to the United States, Australia Japan, Canada, New Zealand, Hong Kong, South Africa or other country where such action as a whole or in part is subject to legal restrictions.
Neither unit rights, units subscribed for ("BTU") or newly issued units have been recommended or approved by any US federal or state securities authority or regulatory authority. No subscription rights, BTA or newly issued shares have been registered or will be registered under the United States Securities Act of 1933, as applicable, or in accordance with applicable laws in the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa or in any other country where the Rights Issue or distribution of the press release is in violation of applicable laws or regulations or presupposes that a further investment memorandum is established, registered or that any other measure is undertaken beyond that required by Swedish law. There is no intention to register any portion of the offer in the United States and the securities issued in the rights issue will not be offered to the public in the United States.
The Company has not authorized any offer to the public with regards to the shares or rights that are referred to in this communication in any member state of the European Economic Area (‘‘EEA’’) besides Sweden. This communication is only addressed to and is only directed at qualified investors in other members states within the EEA member state and in the United Kingdom.
Redwood Pharma AB meddelar sista dag för handel med BTU och första dag för handel med teckningsoptioner av serie TO 5
EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, VARE SIG DIREKT ELLER INDIREKT, I USA, AUSTRALIEN, JAPAN, KANADA, NYA ZEELAND, SYDAFRIKA, HONGKONG, SCHWEIZ, SINGAPORE, SYDKOREA, RYSSLAND, BELARUS ELLER I NÅGON ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING AV DETTA...
ExpreS2ion announces changes to leadership team
Hørsholm, Denmark, 27 September 2023 - ExpreS2ion Biotech Holding AB (“ExpreS2ion” or the “Company”), a pioneer in the development of innovative vaccines for a healthier world, today announced that Dr. Mattis Ranthe, Chief Medical Officer, and Dr. Mette Thorn, Senior Vice President of Preclinical De...
Selektope® ger världens största civila sjukhusfartyg fullständigt skydd mot påväxt av havstulpan trots nära två års sammanräknat stillaliggande i vatten med hög risk för påväxt.
I-Techs antifoulingsubstans Selektope har framgångsrikt stått inför sin tuffaste utmaning hittills, att skydda sjukhusfartyget Global Mercy från påväxt av havstulpan under dess långa perioder av stillaliggande i varma vatten med hög risk för påväxt av havstulpaner. Trots att fartyget sammantaget leg...
Selektope® protects the world's largest hospital ship against barnacle growth despite a combined period of almost two years idling in port at high risk of barnacle fouling.
I-Tech´s antifouling substance, Selektope® has successfully faced its toughest challenge to-date, protecting the hull and niche areas of the world’s largest non-governmental hospital ship from barnacle fouling while docked for extensive periods of time in warm waters, at high risk of fouling. Despit...